Monitoring glucose levels in hospitalized COVID-19 patients with diabetes
Assessment of the Effect of Continuous Glucose Monitorization on Glycemic Variability and Insulin's Prescription in Hospitalized Patients With COVID-19
This study is testing if continuous glucose monitoring can help doctors manage hospitalized COVID-19 patients with diabetes better and understand how their blood sugar levels affect their recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Academic / other |
| Locations | 1 site (Mexico City) |
| Trial ID | NCT05096858 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on hospitalized patients with confirmed COVID-19 pneumonia who also have diabetes mellitus. It aims to assess the impact of continuous glucose monitoring on the management of these patients, particularly in understanding glycemic variability and its potential complications. The study will analyze the correlation between diabetes and the severity of COVID-19 outcomes, including the need for medical interventions and mortality rates. By closely monitoring glucose levels, the study seeks to provide insights into better management strategies for this vulnerable population.
Who should consider this trial
Good fit: Ideal candidates for this study are hospitalized patients diagnosed with COVID-19 pneumonia who also have diabetes mellitus.
Not a fit: Patients who have been hospitalized for less than three days will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management and outcomes for hospitalized patients with diabetes and COVID-19.
How similar studies have performed: While there is limited data on similar studies, the relationship between diabetes and COVID-19 severity has been observed, suggesting potential for impactful findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed COVID-19 pneumonia * Diabetes mellitus Exclusion Criteria: * Less than 3 days of hospital care
Where this trial is running
Mexico City
- National Institute of Medical Sciences and Nutrition Salvador Zubiran — Mexico City, Mexico (Recruiting)
Study contacts
- Principal investigator: Alfonso Gulias Herrero — Incmnsz
- Study coordinator: Alfonso Gulias Herrero
- Email: alfonso.guliash@incmnsz.mx
- Phone: 523123173679
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.